PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases.

Abstract Sjögren syndrome (SS) is frequently associated with ulcerative keratitis, which is difficult to treat due to lacrimal tear deficiency and inflammation of the ocular surface.
PMID
Related Publications

Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.

Effect of a New Matrix Therapy Agent in Persistent Epithelial Defects After Bacterial Keratitis Treated With Topical Fortified Antibiotics.

RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.

Synergistic effect of regenerating agent plus cord blood serum eye drops for the treatment of resistant neurotrophic keratitis: a case report and a hypothesis for pathophysiologic mechanism.

Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29517701
OWN - NLM
STAT- MEDLINE
DCOM- 20180319
LR  - 20180319
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 10
DP  - 2018 Mar
TI  - Evaluation of a new matrix regenerating agent in patients with Sjogren syndrome
      and superficial ulcerative keratitis resistant to conventional therapy: A report 
      of 3 cases.
PG  - e9935
LID - 10.1097/MD.0000000000009935 [doi]
AB  - RATIONALE: Sjogren syndrome (SS) is frequently associated with ulcerative
      keratitis, which is difficult to treat due to lacrimal tear deficiency and
      inflammation of the ocular surface. PATIENT CONCERNS: We report the successful
      additive effect of a matrix regenerating agent (RGTA, Cacicol) in SS patients
      with severe superficial ulcerative keratitis resistant to conventional therapy.
      DIAGNOSES: Retrospective, noncomparative case series of patients with primary or 
      secondary SS associated with chronic diffuse keratitis. INTERVENTIONS: All
      patients (3 women, aged 46, 59, and 84 years) had several years of dry-eye
      disease history and recurrent keratitis despite having used maximal dose topical 
      therapies including artificial tear substitutes, topical vitamin A, and
      cyclosporine 0.05% emulsion. All patients suffered from dry, diffuse, and chronic
      superficial keratitis of at least 75% of the corneal surface, with no sign of
      corneal neovascularization or opacity. OUTCOMES: RGTA treatment led to a rapid
      and marked decrease of ocular pain, burning, irritation, foreign body sensation, 
      and improvement of visual acuity. Total diffuse keratitis healing occurred after 
      several months of treatment. Discontinuation of RGTA administration led to the
      recurrence of severe keratitis; re-introduction of RGTA was successful. No local 
      or systemic adverse effects related to treatment were reported. LESSONS: RGTA
      treatment was effective and safe in this small series of 3 patients suffering
      from SS associated with recurrent or chronic superficial ulcerative keratitis
      resistant to conventional therapy.
FAU - Fajnkuchen, Franck
AU  - Fajnkuchen F
AD  - Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP,
      Paris 13 University, Bobigny.
AD  - Centre d'Imagerie et de Laser, Paris.
FAU - Barritault, Denis
AU  - Barritault D
AD  - Paris Est University, Creteil.
FAU - Giocanti-Auregan, Audrey
AU  - Giocanti-Auregan A
AD  - Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP,
      Paris 13 University, Bobigny.
AD  - CRRET CNRS U 4971, Paris, France.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glycosaminoglycans)
RN  - 0 (OTR4120)
SB  - AIM
SB  - IM
MH  - Administration, Topical
MH  - Aged, 80 and over
MH  - Corneal Ulcer/*drug therapy/etiology
MH  - Female
MH  - Glycosaminoglycans/*administration & dosage
MH  - Humans
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sjogren's Syndrome/*complications
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2018/03/09 06:00
MHDA- 2018/03/20 06:00
CRDT- 2018/03/09 06:00
PHST- 2018/03/09 06:00 [entrez]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
AID - 10.1097/MD.0000000000009935 [doi]
AID - 00005792-201803090-00046 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(10):e9935. doi: 10.1097/MD.0000000000009935.